Duchenne families face heartbreak upon heartbreak with halted gene therapy

Plus: An unusual FDA panel on antidepressant use during pregnancy elevated skeptics of the drugs.

July 26, 2025 Check out STAT+

Sponsored By

Adobe STAT+ | An unusual FDA panel on antidepressant use during pregnancy elevated skeptics of the drugs Makary is recruiting researchers to weigh in on hormone therapy and SSRIs. The panels seem to have a bias, and the FDA's goal is unclear. By Lizzy Lawrence Photo courtesy of Jennifer Hill Blair STAT+ | For many Duchenne families, halt to gene therapy is heartbreak upon heartbreak A muscular dystrophy disease is devastating on its own, but Sarepta Therapeutics' Elevydis, currently shelved, had offered hope. By Jason Mast Molly Ferguson for STAT STAT+ | Drugmakers are racing to help patients stay awake — and could also make billions Takeda, Alkermes, and Centessa lead a race to develop orexin drugs that could transform narcolepsy treatment and tackle a range of other sleep issues. By Elaine Chen Kentucky's campaign to improve rural cancer care is a national model. Federal cuts threaten its progress Kentucky has improved rural cancer care access and quality, but looming Medicaid cuts threaten hospitals, screenings, and preventive services By Ted Alcorn Doctors are biased against higher-weight patients. Can nutrition education help them change? RFK Jr. wants med schools to teach nutrition. Experts call it a chance to teach doctors how to talk about food and weight loss without shaming patients. By Sarah Todd Opinion: My mother refused treatment for her breast cancer. Her doctors should have respected her choice Doctors viewed my mother as a waste of time because she refused breast cancer treatment. But she still deserved their care. By Joy Lisi Rankin STAT+ | A rare drug trial for long Covid failed, yielding lessons on study design The failed drug trial of BC 007 for long Covid reveals the need for better study design, patient-centered research, and focused strategies. By Betsy Ladyzhets — The Sick Times STAT+ | NIH, FDA plan to reduce animal testing draws mixed reactions among scientists Alternatives to animal testing promise to transform basic research and hasten drug development. But what about study areas with no viable substitutes? By Marissa Russo and Jonathan Wosen

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Weekend Reads? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser